Literature DB >> 16965884

European Society of Urogenital Radiology (ESUR) guidelines on the safe use of iodinated contrast media.

Henrik S Thomsen1.   

Abstract

Since 1996 the Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR) has released 19 guidelines regarding safety in relation to the use of radiographic, ultrasonographic as well as magnetic resonance contrast media. The committee has covered both renal and non-renal adverse events as well as other aspects of contrast media. The present paper is an overview of the work accomplished over the last 10 years regarding radiographic iodinated contrast media.

Mesh:

Substances:

Year:  2006        PMID: 16965884     DOI: 10.1016/j.ejrad.2006.06.020

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  25 in total

1.  Comparison of cryoplasty and conventional angioplasty for treating stenotic-occlusive lesions of the femoropopliteal arteries in diabetic patients: immediate, mid-term and long-term results.

Authors:  R Fossaceca; G Guzzardi; M Di Terlizzi; I Divenuto; E Malatesta; P Cerini; C Cusaro; A Carriero
Journal:  Radiol Med       Date:  2012-02-10       Impact factor: 3.469

Review 2.  ST-elevation acute myocardial infarction in pregnancy: 2016 update.

Authors:  Sahar Ismail; Cynthia Wong; Priya Rajan; Mladen I Vidovich
Journal:  Clin Cardiol       Date:  2017-02-13       Impact factor: 2.882

3.  Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies.

Authors:  Lorenzo Preda; Alberto Agazzi; Sara Raimondi; Carla Federica Lanfranchi; Rita Passerini; Albania Calvetta; Giovanni Martinelli; Massimo Bellomi
Journal:  Eur Radiol       Date:  2010-08-02       Impact factor: 5.315

4.  Assessment of acute intestinal graft versus host disease by abdominal magnetic resonance imaging at 3 Tesla.

Authors:  Johannes Budjan; Henrik J Michaely; Ulrike Attenberger; Stefan Haneder; Daniela Heidenreich; Sebastian Kreil; Florian Nolte; Wolf-Karsten Hofmann; Stefan O Schoenberg; Stefan A Klein
Journal:  Eur Radiol       Date:  2014-05-27       Impact factor: 5.315

5.  Potential drug-drug interactions and radiodiagnostic procedures: an in-hospital survey.

Authors:  F Lapi; M Vietri; M Moschini; E Cecchi; A Pugi; E Lucenteforte; G Banchelli; M Di Pirro; E Gallo; A Mugelli; A Vannacci
Journal:  Pharm World Sci       Date:  2010-02-05

6.  2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction.

Authors:  Tomasz Bednarczuk; Thomas H Brix; Wolfgang Schima; Georg Zettinig; George J Kahaly
Journal:  Eur Thyroid J       Date:  2021-06-16

7.  Safety aspects of iodinated contrast media related to their physicochemical properties: a pharmacoepidemiology study in two Tuscany hospitals.

Authors:  Francesco Lapi; Enrica Cecchi; Claudio Pedone; Francesco Attanasio; Grazia Banchelli; Alfredo Vannacci; Marina Di Pirro; Martina Moschini; Valentina Berni; Rosanna Matucci; Elisabetta Cini; Antonino Scalia; Enrico Tendi; Alessandro Mugelli
Journal:  Eur J Clin Pharmacol       Date:  2008-04-10       Impact factor: 2.953

8.  CHA2DS2-VASC Score Predicts Risk of Contrast-Induced Nephropathy in Non-ST Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Interventions.

Authors:  Onur Baydar; Alparslan Kilic
Journal:  Kidney Dis (Basel)       Date:  2019-07-02

9.  Acute hyperglycemia and contrast-induced nephropathy in patients with non-ST elevation myocardial infarction.

Authors:  Onur Baydar; Alparslan Kilic
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-02-21

10.  Preprocedural N-terminal pro-brain natriuretic peptide (NT-proBNP) is similar to the Mehran contrast-induced nephropathy (CIN) score in predicting CIN following elective coronary angiography.

Authors:  Yong Liu; Yi-ting He; Ning Tan; Ji-yan Chen; Yuan-hui Liu; Da-hao Yang; Shui-jin Huang; Piao Ye; Hua-long Li; Peng Ran; Chong-yang Duan; Shi-qun Chen; Ying-ling Zhou; Ping-yan Chen
Journal:  J Am Heart Assoc       Date:  2015-04-17       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.